Lipid nanoparticles for targeted siRNA delivery - going from bench to bedside.

Systemic delivery of factor IX messenger RNA for protein replacement therapy. Proc Natl Acad Sci U S A (2017) 0.75

Rational design of cationic lipids for siRNA delivery. Nat Biotechnol (2010) 4.97

Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet (2010) 4.52

Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med (2014) 4.41

Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci U S A (2010) 4.25

Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res (2005) 4.24

Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med (2013) 3.97

Delivery materials for siRNA therapeutics. Nat Mater (2013) 3.70

Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci (2007) 3.59

Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther (2010) 3.26

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet (2013) 3.10

Non-viral vectors for gene-based therapy. Nat Rev Genet (2014) 3.04

Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol (2013) 2.81

Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res (2013) 2.41

Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol (2013) 1.97

mRNA-based therapeutics--developing a new class of drugs. Nat Rev Drug Discov (2014) 1.87

Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Control Release (2013) 1.64

Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route. J Biol Chem (2009) 1.49

Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol Ther (2013) 1.42

Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells. Mol Ther Nucleic Acids (2012) 1.24

Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin Cancer Res (2013) 1.21

Knocking down disease: a progress report on siRNA therapeutics. Nat Rev Genet (2015) 1.19

Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment. Transl Oncol (2015) 1.12

siRNA Versus miRNA as Therapeutics for Gene Silencing. Mol Ther Nucleic Acids (2015) 1.12

Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol Ther (2013) 1.11

Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity. Adv Drug Deliv Rev (2005) 1.10

Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med (2015) 1.07

Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid:plasmid DNA complexes in mice. Hum Gene Ther (2000) 1.07

Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer. Oncogene (2013) 1.05

Cubic phases in phosphatidylcholine-cholesterol mixtures: cholesterol as membrane "fusogen". Biophys J (2006) 1.03

Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nat Rev Drug Discov (2015) 1.02

Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev (2015) 1.01

RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise? Annu Rev Pharmacol Toxicol (2016) 1.01

Mechanisms of nanoparticle-mediated siRNA transfection by melittin-derived peptides. ACS Nano (2013) 0.95

Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine. Nanomedicine (Lond) (2014) 0.94

Lipid nanoparticle delivery systems for siRNA-based therapeutics. Drug Deliv Transl Res (2014) 0.92

Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. Antiviral Res (2015) 0.92

Pegaptanib in the treatment of wet, age-related macular degeneration. Int J Nanomedicine (2006) 0.88

Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles. ACS Nano (2015) 0.88

Efficient Biodistribution and Gene Silencing in the Lung epithelium via Intravenous Liposomal Delivery of siRNA. Mol Ther Nucleic Acids (2013) 0.86

Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles. ACS Nano (2015) 0.86

Delivery and targeting of miRNAs for treating liver fibrosis. Pharm Res (2014) 0.85

Development of small RNA delivery systems for lung cancer therapy. Int J Mol Sci (2015) 0.85

Towards nanomedicines of the future: Remote magneto-mechanical actuation of nanomedicines by alternating magnetic fields. J Control Release (2015) 0.85

Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration. J Control Release (2014) 0.84

Shielding of Lipid Nanoparticles for siRNA Delivery: Impact on Physicochemical Properties, Cytokine Induction, and Efficacy. Mol Ther Nucleic Acids (2014) 0.84

Silencing of ANGPTL 3 (angiopoietin-like protein 3) in human hepatocytes results in decreased expression of gluconeogenic genes and reduced triacylglycerol-rich VLDL secretion upon insulin stimulation. Biosci Rep (2014) 0.83

Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis. Amyloid (2016) 0.82

Transforming Nanomedicines From Lab Scale Production to Novel Clinical Modality. Bioconjug Chem (2016) 0.81

Functionalized liposomes loaded with siRNAs targeting ion channels in effector memory T cells as a potential therapy for autoimmunity. Biomaterials (2013) 0.81

Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies. Proc Natl Acad Sci U S A (2015) 0.81

Chemical and structural modifications of RNAi therapeutics. Adv Drug Deliv Rev (2015) 0.80

Technologies for controlled, local delivery of siRNA. J Control Release (2015) 0.80

Effect of surface properties on liposomal siRNA delivery. Biomaterials (2015) 0.80

A role for peptides in overcoming endosomal entrapment in siRNA delivery - A focus on melittin. Biotechnol Adv (2015) 0.79

Therapeutic microRNA Delivery Strategies with Special Emphasis on Cancer Therapy and Tumorigenesis: Current Trends and Future Challenges. Curr Drug Metab (2016) 0.79

Guanabenz (Wytensin™) selectively enhances uptake and efficacy of hydrophobically modified siRNAs. Nucleic Acids Res (2015) 0.78

Identification of siRNA delivery enhancers by a chemical library screen. Nucleic Acids Res (2015) 0.78

The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery. Adv Drug Deliv Rev (2016) 0.78

Bridging small interfering RNA with giant therapeutic outcomes using nanometric liposomes. J Control Release (2015) 0.78

The effect of neutral helper lipids on the structure of cationic lipid monolayers. J R Soc Interface (2011) 0.78

Lipid nanoparticles for short interfering RNA delivery. Adv Genet (2014) 0.78

Effect of combination therapy of siRNA targeting growth hormone receptor and 5-fluorouracil in hepatic metastasis of colon cancer. Oncol Lett (2015) 0.77

Enhancing siRNA delivery by employing lipid nanoparticles. Ther Deliv (2014) 0.77

Clinical and genetic analysis of a family diagnosed with familial hypobetalipoproteinemia in which the proband was diagnosed with diabetes mellitus. Atherosclerosis (2015) 0.76